ReviewClinical parkinsonism & related disorders2026
Prevalence and treatment effects on non-motor symptoms in cervical dystonia: A systematic review and meta-analysis.
Review in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Non-motor symptoms (NMS) substantially impair quality of life in patients with cervical dystonia (CD). Although psychiatric comorbidities are well recognized, the prevalence of sleep disturbance and fatigue in this population remains unclear; likewise, whether therapeutic interventions ameliorate NMS has not been established. This systematic review and meta-analysis evaluated NMS prevalence, identified moderators of heterogeneity, and assessed treatment effects on NMS in patients with CD. Methods: Following PRISMA standards (PROSPERO: CRD42024619105), we searched Embase, PsycINFO, PubMed, and Web of Science through May 1, 2026. We calculated pooled prevalence using random-effects models, and conducted subgroup analyses and meta-regression to identify sources of heterogeneity. Treatment outcomes were assessed using standardized mean differences. Results: Forty-two studies were included. Pooled prevalence rates were: depression 35.2% (95% CI, 30.0% to 40.6%; I Conclusion: NMS were highly prevalent in CD, with over half of patients reporting sleep disturbance or fatigue. Assessment tool type was the most consistent source of heterogeneity across outcomes, highlighting the need for standardized NMS assessment protocols. Meta-regression identified female percentage as a potential moderator of depression prevalence. Among interventions, BoNT provided preliminary evidence of modest benefit for mood symptoms but had no effect on sleep. The evidence base for NMS interventions in CD remains preliminary, underscoring the need for trials explicitly aimed at NMS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.